Cardiac Arrest
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Paroxysmal ventricular tachycardia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Sick Sinus Syndrome
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Syncope
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Supraventricular tachycardia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Ventricular Fibrillation
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
First degree atrioventricular block
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Right bundle branch block
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Trifascicular block
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
ST segment elevation (finding)
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
AV Block First Degree by ECG Finding
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Experimental Autoimmune Encephalomyelitis
|
0.200 |
Biomarker
|
disease |
RGD |
The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat.
|
8557821 |
1995 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
Identification of a new co-factor, MOG1, required for the full function of cardiac sodium channel Nav 1.5.
|
18184654 |
2008 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
MOG1 was screened by direct sequencing in patients with BrS and idiopathic ventricular fibrillation.
|
21447824 |
2011 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias.
|
21621375 |
2011 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
BEFREE |
MOG1 was screened by direct sequencing in patients with BrS and idiopathic ventricular fibrillation.
|
21447824 |
2011 |
Cardiac Arrhythmia
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias.
|
21621375 |
2011 |
Paroxysmal familial ventricular fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
MOG1 was screened by direct sequencing in patients with BrS and idiopathic ventricular fibrillation.
|
21447824 |
2011 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
BEFREE |
Previously, the genes SCN1B, SCN3B, MOG1, and KCND3 have been associated with BrS.
|
22284586 |
2012 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
Use of MOG1 to enhance Na(v)1.5 trafficking to PM may be a potential personalized therapeutic approach for some patients with Brugada syndrome, dilated cardiomyopathy, and sick sinus syndrome in the future.
|
23420830 |
2013 |
Brugada Syndrome (disorder)
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
The nonsense p.E61X genetic variation in the RANGRF gene has been postulated as responsible for Brugada syndrome although no clear association has been established.
|
24142675 |
2014 |
Brugada Syndrome (disorder)
|
0.550 |
GeneticVariation
|
disease |
ORPHANET |
The nonsense p.E61X genetic variation in the RANGRF gene has been postulated as responsible for Brugada syndrome although no clear association has been established.
|
24142675 |
2014 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
The nonsense p.E61X genetic variation in the RANGRF gene has been postulated as responsible for Brugada syndrome although no clear association has been established.
|
24142675 |
2014 |
Brugada Syndrome (disorder)
|
0.550 |
Biomarker
|
disease |
CLINGEN |
Compared with wild type MOG1 or control EGFP, mutant MOG1 with mutation E83D associated with Brugada syndrome significantly decreases the HR.
|
26903377 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |